Sonnet BioTherapeutics Ownership 2024 | Who Owns Sonnet BioTherapeutics Now?

Overview RevenueFinancials Chart

Institutional Ownership

0.05%

Insider Ownership

5.44%

Retail Ownership

94.51%

Institutional Holders

1.00

Sonnet BioTherapeutics Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ANSON FUNDS MANAGEMENT LP	40.87%	0.10%	1,760,000	1,760,000	100.00%	633,600,000	Mar 31, 2023
WALLEYE CAPITAL LLC	38.65%	0.01%	1,664,595	1,664,595	100.00%	599,254,000	Mar 31, 2023
SABBY MANAGEMENT, LLC	28.22%	0.38%	1,215,534	1,215,534	100.00%	437,592,000	Mar 31, 2023
ALYESKA INVESTMENT GROUP, L.P.	22.10%	0.00%	951,806	951,806	100.00%	342,650,000	Mar 31, 2023
ALYESKA INVESTMENT GROUP, L.P.	19.69%	0.00%	848,000	848,000	100.00%	305,280,000	Mar 31, 2023
AYRTON CAPITAL LLC	17.77%	0.99%	765,425	765,425	100.00%	275,553,000	Mar 31, 2023
CVI HOLDINGS, LLC	16.29%	0.10%	701,634	701,634	100.00%	252,588,000	Mar 31, 2023
BOOTHBAY FUND MANAGEMENT, LLC	3.16%	0.00%	136,231	136,231	100.00%	49,043,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.67%	-	28,916	-551	-1.87%	10,409,000	Mar 31, 2023
VANGUARD GROUP INC	0.42%	-	18,057	-	-	6,501,000	Mar 31, 2023
NORTHERN TRUST CORP	0.41%	-	17,853	17,853	100.00%	6,427,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	0.38%	-	16,200	16,200	100.00%	6,000	Mar 31, 2023
BLACKROCK INC.	0.30%	-	13,104	-	-	4,718,000	Mar 31, 2023
ADVISORY SERVICES NETWORK, LLC	0.27%	0.00%	11,438	2,116	22.70%	4,118,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.12%	0.00%	5,202	-4,122	-44.21%	2,000	Mar 31, 2023
MORGAN STANLEY	0.03%	-	1,141	-	-	411,000	Mar 31, 2023
IFP ADVISORS, INC	0.00%	-	142	-	-	244,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	59	9	18.00%	21,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	2	-	-	1,000	Mar 31, 2023
MARINER, LLC	-	-	-	-13,533	-100.00%	-	Mar 31, 2023

Sonnet BioTherapeutics's largest institutional shareholder is ANSON FUNDS MANAGEMENT LP, holding 40.87% of the company's total share outstanding, currently valued at $633.60M. The top 10 institutional shareholders own together 187.85% of the company.

Institutional Shareholders by % of Total Assets

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
AYRTON CAPITAL LLC	17.77%	0.99%	765,425	765,425	100.00%	275,553,000	Mar 31, 2023
SABBY MANAGEMENT, LLC	28.22%	0.38%	1,215,534	1,215,534	100.00%	437,592,000	Mar 31, 2023
ANSON FUNDS MANAGEMENT LP	40.87%	0.10%	1,760,000	1,760,000	100.00%	633,600,000	Mar 31, 2023
CVI HOLDINGS, LLC	16.29%	0.10%	701,634	701,634	100.00%	252,588,000	Mar 31, 2023
WALLEYE CAPITAL LLC	38.65%	0.01%	1,664,595	1,664,595	100.00%	599,254,000	Mar 31, 2023
ALYESKA INVESTMENT GROUP, L.P.	22.10%	0.00%	951,806	951,806	100.00%	342,650,000	Mar 31, 2023
ALYESKA INVESTMENT GROUP, L.P.	19.69%	0.00%	848,000	848,000	100.00%	305,280,000	Mar 31, 2023
BOOTHBAY FUND MANAGEMENT, LLC	3.16%	0.00%	136,231	136,231	100.00%	49,043,000	Mar 31, 2023
ADVISORY SERVICES NETWORK, LLC	0.27%	0.00%	11,438	2,116	22.70%	4,118,000	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.12%	0.00%	5,202	-4,122	-44.21%	2,000	Mar 31, 2023
IFP ADVISORS, INC	0.00%	-	142	-	-	244,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	0.38%	-	16,200	16,200	100.00%	6,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.67%	-	28,916	-551	-1.87%	10,409,000	Mar 31, 2023
NORTHERN TRUST CORP	0.41%	-	17,853	17,853	100.00%	6,427,000	Mar 31, 2023
VANGUARD GROUP INC	0.42%	-	18,057	-	-	6,501,000	Mar 31, 2023
BLACKROCK INC.	0.30%	-	13,104	-	-	4,718,000	Mar 31, 2023
MORGAN STANLEY	0.03%	-	1,141	-	-	411,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	59	9	18.00%	21,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	2	-	-	1,000	Mar 31, 2023
MARINER, LLC	-	-	-	-13,533	-100.00%	-	Mar 31, 2023

The largest Sonnet BioTherapeutics shareholder by % of total assets is AYRTON CAPITAL LLC. The company owns 765.42K shares of Sonnet BioTherapeutics (SONN), representing 0.99% of its total assets.

Institutional Buyers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ANSON FUNDS MANAGEMENT LP	40.87%	0.10%	1,760,000	1,760,000	100.00%	633,600,000	Mar 31, 2023
WALLEYE CAPITAL LLC	38.65%	0.01%	1,664,595	1,664,595	100.00%	599,254,000	Mar 31, 2023
SABBY MANAGEMENT, LLC	28.22%	0.38%	1,215,534	1,215,534	100.00%	437,592,000	Mar 31, 2023
ALYESKA INVESTMENT GROUP, L.P.	22.10%	0.00%	951,806	951,806	100.00%	342,650,000	Mar 31, 2023
ALYESKA INVESTMENT GROUP, L.P.	19.69%	0.00%	848,000	848,000	100.00%	305,280,000	Mar 31, 2023
AYRTON CAPITAL LLC	17.77%	0.99%	765,425	765,425	100.00%	275,553,000	Mar 31, 2023
CVI HOLDINGS, LLC	16.29%	0.10%	701,634	701,634	100.00%	252,588,000	Mar 31, 2023
BOOTHBAY FUND MANAGEMENT, LLC	3.16%	0.00%	136,231	136,231	100.00%	49,043,000	Mar 31, 2023
NORTHERN TRUST CORP	0.41%	-	17,853	17,853	100.00%	6,427,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	0.38%	-	16,200	16,200	100.00%	6,000	Mar 31, 2023
ADVISORY SERVICES NETWORK, LLC	0.27%	0.00%	11,438	2,116	22.70%	4,118,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	59	9	18.00%	21,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	2	-	-	1,000	Mar 31, 2023
MORGAN STANLEY	0.03%	-	1,141	-	-	411,000	Mar 31, 2023
BLACKROCK INC.	0.30%	-	13,104	-	-	4,718,000	Mar 31, 2023
VANGUARD GROUP INC	0.42%	-	18,057	-	-	6,501,000	Mar 31, 2023
IFP ADVISORS, INC	0.00%	-	142	-	-	244,000	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.67%	-	28,916	-551	-1.87%	10,409,000	Mar 31, 2023
UBS GROUP AG	-	-	-	-2,815	-100.00%	-	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.12%	0.00%	5,202	-4,122	-44.21%	2,000	Mar 31, 2023

As of Mar 31 2023, Sonnet BioTherapeutics's largest institutional buyer is ANSON FUNDS MANAGEMENT LP. The company purchased 1.76M stocks of SONN, valued at $633.60M.

Institutional Sellers

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TWO SIGMA SECURITIES, LLC	-	-	-	-18,003	-100.00%	-	Mar 31, 2023
HRT FINANCIAL LP	-	-	-	-15,930	-100.00%	-	Mar 31, 2023
MARINER, LLC	-	-	-	-13,533	-100.00%	-	Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)	0.12%	0.00%	5,202	-4,122	-44.21%	2,000	Mar 31, 2023
UBS GROUP AG	-	-	-	-2,815	-100.00%	-	Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC	0.67%	-	28,916	-551	-1.87%	10,409,000	Mar 31, 2023
IFP ADVISORS, INC	0.00%	-	142	-	-	244,000	Mar 31, 2023
VANGUARD GROUP INC	0.42%	-	18,057	-	-	6,501,000	Mar 31, 2023
BLACKROCK INC.	0.30%	-	13,104	-	-	4,718,000	Mar 31, 2023
MORGAN STANLEY	0.03%	-	1,141	-	-	411,000	Mar 31, 2023
BANK OF AMERICA CORP /DE/	-	-	2	-	-	1,000	Mar 31, 2023
WELLS FARGO & COMPANY/MN	0.00%	-	59	9	18.00%	21,000	Mar 31, 2023
ADVISORY SERVICES NETWORK, LLC	0.27%	0.00%	11,438	2,116	22.70%	4,118,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	0.38%	-	16,200	16,200	100.00%	6,000	Mar 31, 2023
NORTHERN TRUST CORP	0.41%	-	17,853	17,853	100.00%	6,427,000	Mar 31, 2023
BOOTHBAY FUND MANAGEMENT, LLC	3.16%	0.00%	136,231	136,231	100.00%	49,043,000	Mar 31, 2023
CVI HOLDINGS, LLC	16.29%	0.10%	701,634	701,634	100.00%	252,588,000	Mar 31, 2023
AYRTON CAPITAL LLC	17.77%	0.99%	765,425	765,425	100.00%	275,553,000	Mar 31, 2023
ALYESKA INVESTMENT GROUP, L.P.	19.69%	0.00%	848,000	848,000	100.00%	305,280,000	Mar 31, 2023
ALYESKA INVESTMENT GROUP, L.P.	22.10%	0.00%	951,806	951,806	100.00%	342,650,000	Mar 31, 2023

As of Mar 31 2023, Sonnet BioTherapeutics's biggest institutional seller is TWO SIGMA SECURITIES, LLC. The company sold -18.00K shares of SONN, valued at -.

Institutional New positions

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
ANSON FUNDS MANAGEMENT LP	40.87%	0.10%	1,760,000	1,760,000	100.00%	633,600,000	Mar 31, 2023
WALLEYE CAPITAL LLC	38.65%	0.01%	1,664,595	1,664,595	100.00%	599,254,000	Mar 31, 2023
SABBY MANAGEMENT, LLC	28.22%	0.38%	1,215,534	1,215,534	100.00%	437,592,000	Mar 31, 2023
ALYESKA INVESTMENT GROUP, L.P.	22.10%	0.00%	951,806	951,806	100.00%	342,650,000	Mar 31, 2023
ALYESKA INVESTMENT GROUP, L.P.	19.69%	0.00%	848,000	848,000	100.00%	305,280,000	Mar 31, 2023
AYRTON CAPITAL LLC	17.77%	0.99%	765,425	765,425	100.00%	275,553,000	Mar 31, 2023
CVI HOLDINGS, LLC	16.29%	0.10%	701,634	701,634	100.00%	252,588,000	Mar 31, 2023
BOOTHBAY FUND MANAGEMENT, LLC	3.16%	0.00%	136,231	136,231	100.00%	49,043,000	Mar 31, 2023
NORTHERN TRUST CORP	0.41%	-	17,853	17,853	100.00%	6,427,000	Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC	0.38%	-	16,200	16,200	100.00%	6,000	Mar 31, 2023

Sonnet BioTherapeutics's largest new institutional shareholder by number of shares is ANSON FUNDS MANAGEMENT LP, purchased 1.76M shares, valued at $633.60M, as of undefined.

Institutional Sold Out

Name	% Total Shares	% Total Assets	Current Shares	Change Amount	Change %	Market Value	Date
TWO SIGMA SECURITIES, LLC	-	-	-	-18,003	-100.00%	-	Mar 31, 2023
HRT FINANCIAL LP	-	-	-	-15,930	-100.00%	-	Mar 31, 2023
MARINER, LLC	-	-	-	-13,533	-100.00%	-	Mar 31, 2023
UBS GROUP AG	-	-	-	-2,815	-100.00%	-	Mar 31, 2023

Sonnet BioTherapeutics's largest sold out institutional shareholder by shares sold is TWO SIGMA SECURITIES, LLC, sold -18.00K shares, valued at -, as of undefined.

Sonnet BioTherapeutics Mutual Fund Holders

Name	% Total Assets	Total Shares	Change Amount	Change %	Date
FIDELITY COMMONWEALTH TRUST	0.15%	467,345	-	-	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	1,873,368	-	-	Mar 31, 2024
FIDELITY CONCORD STREET TRUST	0.00%	705,533	-	-	Feb 29, 2024
FIDELITY CONCORD STREET TRUST	0.00%	9,159	1,507	19.69%	Feb 29, 2024
VANGUARD INDEX FUNDS	0.00%	14,726	-14,726	-50.00%	Mar 31, 2024
EQ ADVISORS TRUST	0.00%	3,763	-	-	Mar 31, 2024

Sonnet BioTherapeutics's largest mutual fund holder by % of total assets is "FIDELITY COMMONWEALTH TRUST", owning 467.35K shares, compromising 0.15% of its total assets.

Sonnet BioTherapeutics Institutional Ownership Trends

Institutional Holdings Trend

Date	Holdings	Change %
30 Sep, 22	1	-94.44%
30 Jun, 22	18	-14.29%
31 Mar, 22	21	31.25%
31 Dec, 21	16	23.08%
30 Sep, 21	13	30.00%
30 Jun, 21	10	-33.33%
31 Mar, 21	15	66.67%
31 Dec, 20	9	-
30 Sep, 20	9	125.00%
30 Jun, 20	4	-

As of 30 Sep 22, 1 institutions are holding Sonnet BioTherapeutics's shares, representing a decrease of -94.44% compared to the previous quarter.

Shares Outstanding Trend

Date	Shares Outstanding	Change %
30 Sep, 22	2,000	-99.94%
30 Jun, 22	3,519,106	-41.21%
31 Mar, 22	5,985,793	50.03%
31 Dec, 21	3,989,736	42.96%
30 Sep, 21	2,790,790	164.02%
30 Jun, 21	1,057,042	45.87%
31 Mar, 21	724,669	58.56%
31 Dec, 20	457,020	20.52%
30 Sep, 20	379,210	49.70%
30 Jun, 20	253,320	-

Sonnet BioTherapeutics (SONN) has 2.00K shares outstanding as of 30 Sep 22, down -99.94% compared to the previous quarter.

Institutional Ownership Trend

Date	Ownership %	Change %
30 Sep, 22	0.05%	0.00%
30 Jun, 22	92.66%	0.37%
31 Mar, 22	157.61%	1.43%
31 Dec, 21	105.06%	1.95%
30 Sep, 21	73.49%	9.49%
30 Jun, 21	27.83%	7.64%
31 Mar, 21	19.08%	13.18%
31 Dec, 20	12.03%	12.07%
30 Sep, 20	9.99%	22.44%
30 Jun, 20	6.67%	-

As of 30 Sep 22, Sonnet BioTherapeutics is held by 0.05% institutional shareholders, representing a 0.00% growth compared to 30 Jun 22.

Institutional Increased Positions Trend

Date	Increased Positions	Change %
30 Sep, 22	-	-100.00%
30 Jun, 22	6	-53.85%
31 Mar, 22	13	62.50%
31 Dec, 21	8	33.33%
30 Sep, 21	6	50.00%
30 Jun, 21	4	-60.00%
31 Mar, 21	10	11.11%
31 Dec, 20	9	28.57%
30 Sep, 20	7	75.00%
30 Jun, 20	4	-

- institutional shareholders have increased their position in SONN stock as of 30 Sep 22 compared to 6 in the previous quarter (a -100.00% decrease).

Institutional Reduced Positions Trend

Date	Reduced Positions	Change %
30 Sep, 22	-	-100.00%
30 Jun, 22	6	100.00%
31 Mar, 22	3	200.00%
31 Dec, 21	1	-
30 Sep, 21	1	-
30 Jun, 21	1	-
31 Mar, 21	1	-
31 Dec, 20	-	-100.00%
30 Sep, 20	2	-
30 Jun, 20	-	-

- institutional shareholders have reduced their position in SONN stock as of 30 Sep 22 compared to 6 in the previous quarter (a -100.00% decrease).

All Institutional Ownership Trend Data

Date	Holdings	Change %	Shares Outstanding	Change %	Ownership %	Change %	Increased Positions	Change %	Reduced Positions	Change %
30 Sep, 22	1	-94.44%	2,000	-99.94%	0.05%	0.00%	-	-100.00%	-	-100.00%
30 Jun, 22	18	-14.29%	3,519,106	-41.21%	92.66%	0.37%	6	-53.85%	6	100.00%
31 Mar, 22	21	31.25%	5,985,793	50.03%	157.61%	1.43%	13	62.50%	3	200.00%
31 Dec, 21	16	23.08%	3,989,736	42.96%	105.06%	1.95%	8	33.33%	1	-
30 Sep, 21	13	30.00%	2,790,790	164.02%	73.49%	9.49%	6	50.00%	1	-
30 Jun, 21	10	-33.33%	1,057,042	45.87%	27.83%	7.64%	4	-60.00%	1	-
31 Mar, 21	15	66.67%	724,669	58.56%	19.08%	13.18%	10	11.11%	1	-
31 Dec, 20	9	-	457,020	20.52%	12.03%	12.07%	9	28.57%	-	-100.00%
30 Sep, 20	9	125.00%	379,210	49.70%	9.99%	22.44%	7	75.00%	2	-
30 Jun, 20	4	-	253,320	-	6.67%	-	4	-	-	-

Sonnet BioTherapeutics Insider Shareholders Trades

Open Market Insider Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Oct 27, 2023	Rao Raghu	director	-	P-Purchase	Buy	31,250	$1.60	$50.00K	31,250
Oct 27, 2023	Rao Raghu	director	-	P-Purchase	Buy	15,625	$1.60	$25.00K	16,813
Oct 27, 2023	Mohan Pankaj	director, officer	Chairman, President and CEO	P-Purchase	Buy	68,750	$1.60	$110.00K	68,750
Oct 27, 2023	Mohan Pankaj	director, officer	Chairman, President and CEO	P-Purchase	Buy	34,375	$1.60	$55.00K	59,526
Jun 15, 2023	Dexter Susan	officer	Chief Technical Officer	P-Purchase	Buy	10,000	$0.70	$7.00K	33,667
May 31, 2023	Dyrness Albert D.	director	-	P-Purchase	Buy	23,255	$0.47	$10.88K	28,962
May 18, 2023	Bhatt Nailesh	director	-	P-Purchase	Buy	25,000	$0.23	$5.80K	30,733
May 15, 2023	Mohan Pankaj	director, officer	Chairman, President and CEO	P-Purchase	Buy	371,600	$0.22	$82.87K	553,331
Mar 16, 2023	Mohan Pankaj	director, officer	Chairman, President and CEO	P-Purchase	Buy	60,000	$0.58	$35.10K	181,731

Open Market Insider Buys

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Oct 27, 2023	Rao Raghu	director	-	P-Purchase	Buy	31,250	$1.60	$50.00K	31,250
Oct 27, 2023	Rao Raghu	director	-	P-Purchase	Buy	15,625	$1.60	$25.00K	16,813
Oct 27, 2023	Mohan Pankaj	director, officer	Chairman, President and CEO	P-Purchase	Buy	68,750	$1.60	$110.00K	68,750
Oct 27, 2023	Mohan Pankaj	director, officer	Chairman, President and CEO	P-Purchase	Buy	34,375	$1.60	$55.00K	59,526
Jun 15, 2023	Dexter Susan	officer	Chief Technical Officer	P-Purchase	Buy	10,000	$0.70	$7.00K	33,667
May 31, 2023	Dyrness Albert D.	director	-	P-Purchase	Buy	23,255	$0.47	$10.88K	28,962
May 18, 2023	Bhatt Nailesh	director	-	P-Purchase	Buy	25,000	$0.23	$5.80K	30,733
May 15, 2023	Mohan Pankaj	director, officer	Chairman, President and CEO	P-Purchase	Buy	371,600	$0.22	$82.87K	553,331
Mar 16, 2023	Mohan Pankaj	director, officer	Chairman, President and CEO	P-Purchase	Buy	60,000	$0.58	$35.10K	181,731

Insider Sells

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Sep 07, 2023	Markey John	10 percent owner	-		Sell	-	-	-	186,430
Feb 17, 2023	Mohan Pankaj	director, officer	Chairman, President and CEO	D-Return	Sell	73,561	-	$7.36	48,170
Feb 17, 2023	Dexter Susan	officer	Chief Technical Officer	D-Return	Sell	14,627	-	$1.46	9,040
Feb 17, 2023	Kenney Richard T	officer	Chief Medical Officer	D-Return	Sell	14,627	-	$1.46	3,571
Feb 17, 2023	Cini John K.	officer	Chief Scientific Officer	D-Return	Sell	18,551	-	$1.86	21,720
Feb 17, 2023	Cross John Harry III	officer	Chief Financial Officer	F-InKind	Sell	1,960	$1.06	$2.08K	23,927

All Insider Owners Trades

Date	Name	Relation	Role	Transaction	Buy/Sell	Shares	Price	Value	Shares Held
Oct 27, 2023	Rao Raghu	director	-	P-Purchase	Buy	31,250	$1.60	$50.00K	31,250
Oct 27, 2023	Rao Raghu	director	-	P-Purchase	Buy	15,625	$1.60	$25.00K	16,813
Oct 27, 2023	Mohan Pankaj	director, officer	Chairman, President and CEO	P-Purchase	Buy	68,750	$1.60	$110.00K	68,750
Oct 27, 2023	Mohan Pankaj	director, officer	Chairman, President and CEO	P-Purchase	Buy	34,375	$1.60	$55.00K	59,526
Sep 07, 2023	Markey John	10 percent owner	-		Sell	-	-	-	186,430
Jun 15, 2023	Dexter Susan	officer	Chief Technical Officer	P-Purchase	Buy	10,000	$0.70	$7.00K	33,667
May 31, 2023	Dyrness Albert D.	director	-	P-Purchase	Buy	23,255	$0.47	$10.88K	28,962
May 18, 2023	Bhatt Nailesh	director	-	P-Purchase	Buy	25,000	$0.23	$5.80K	30,733
May 15, 2023	Mohan Pankaj	director, officer	Chairman, President and CEO	P-Purchase	Buy	371,600	$0.22	$82.87K	553,331
Mar 16, 2023	Mohan Pankaj	director, officer	Chairman, President and CEO	P-Purchase	Buy	60,000	$0.58	$35.10K	181,731
Feb 17, 2023	Mohan Pankaj	director, officer	Chairman, President and CEO	A-Award	Buy	73,561	-	$7.36	121,731
Feb 17, 2023	Mohan Pankaj	director, officer	Chairman, President and CEO	D-Return	Sell	73,561	-	$7.36	48,170
Feb 17, 2023	Dexter Susan	officer	Chief Technical Officer	A-Award	Buy	14,627	-	$1.46	23,667
Feb 17, 2023	Dexter Susan	officer	Chief Technical Officer	D-Return	Sell	14,627	-	$1.46	9,040
Feb 17, 2023	Kenney Richard T	officer	Chief Medical Officer	A-Award	Buy	14,627	-	$1.46	18,198
Feb 17, 2023	Kenney Richard T	officer	Chief Medical Officer	D-Return	Sell	14,627	-	$1.46	3,571
Feb 17, 2023	Cini John K.	officer	Chief Scientific Officer	A-Award	Buy	18,551	-	$1.86	40,271
Feb 17, 2023	Cini John K.	officer	Chief Scientific Officer	D-Return	Sell	18,551	-	$1.86	21,720
Feb 17, 2023	Cross John Harry III	officer	Chief Financial Officer	F-InKind	Sell	1,960	$1.06	$2.08K	23,927
Feb 17, 2023	Griffith Donald J.	director	-	A-Award	Buy	3,214	-	$0.32	10,798

The last insider sell of Sonnet BioTherapeutics's stock was made by Markey John on Sep 07 2023, selling - shares at - per share (valued at -). The last insider buy of SONN was made by Rao Raghu on Oct 27 2023, buying 31,250 shares at $1.60 per share (worth $50.00K).

Sonnet BioTherapeutics Insider Ownership Trends

All Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q4 2023	4	-	-
Q3 2023	-	1	-
Q2 2023	4	-	-
Q1 2023	5	6	83.33%
Q4 2022	10	-	-
Q3 2022	-	-	-
Q2 2022	-	1	-
Q4 2021	8	-	-
Q2 2021	4	3	133.33%
Q1 2021	1	-	-
Q3 2020	9	-	-
Q2 2020	13	-	-
Q1 2020	4	-	-
Q4 2019	5	1	500.00%
Q3 2019	3	-	-
Q2 2019	23	3	766.67%
Q1 2019	2	-	-
Q4 2018	14	3	466.67%
Q3 2018	5	-	-
Q2 2018	8	18	44.44%

4 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Sonnet BioTherapeutics's insiders, as of Q4 2023.

Open Market Insider Trades Trend

Date	Buy	Sell	Buy/Sell Ratio
Q4 2023	4	-	-
Q3 2023	-	-	-
Q2 2023	4	-	-
Q1 2023	1	-	-
Q4 2022	-	-	-
Q3 2022	-	-	-
Q2 2022	-	-	-
Q4 2021	-	-	-
Q2 2021	4	-	-
Q1 2021	-	-	-
Q3 2020	-	-	-
Q2 2020	2	-	-
Q1 2020	4	-	-
Q4 2019	4	-	-
Q3 2019	3	-	-
Q2 2019	5	-	-
Q1 2019	2	-	-
Q4 2018	14	-	-
Q3 2018	2	-	-
Q2 2018	5	18	27.78%

As of Q4 2023, Insider owners conducted 4 open market buy trades and 0 open market sell trades of Sonnet BioTherapeutics's stocks.

Sonnet BioTherapeutics Peer Ownership

Ticker	Company
ZVSA	ZyVersa Therapeutics, Inc.
CNSP	CNS Pharmaceuticals, Inc.
YS	LakeShore Biopharma Co., Ltd
EFTR	eFFECTOR Therapeutics, Inc.
ALLR	Allarity Therapeutics, Inc.
IMMX	Immix Biopharma, Inc.

SONN Ownership FAQ

Who Owns Sonnet BioTherapeutics?

Sonnet BioTherapeutics is owned by institutional shareholders (0.05%), insiders (5.44%), and public (94.51%). The largest institutional shareholder of Sonnet BioTherapeutics is ANSON FUNDS MANAGEMENT LP (40.87% of total shares) and the top mutual fund owner is FIDELITY COMMONWEALTH TRUST (0.15% of total shares).

Who are the major institutional shareholders of Sonnet BioTherapeutics?

Sonnet BioTherapeutics's major institutional shareholders are ANSON FUNDS MANAGEMENT LP, WALLEYE CAPITAL LLC, SABBY MANAGEMENT, LLC, ALYESKA INVESTMENT GROUP, L.P., and ALYESKA INVESTMENT GROUP, L.P.. The top five shareholders own together 149.53% of the company's share outstanding.

How many Sonnet BioTherapeutics shareholders are there?

As of Sep 2022, there are 1 institutional shareholders of Sonnet BioTherapeutics.

What percentage of Sonnet BioTherapeutics is owned by ANSON FUNDS MANAGEMENT LP?

ANSON FUNDS MANAGEMENT LP owns 1.76M shares of Sonnet BioTherapeutics, representing 40.87% of the company's total shares outstanding, valued at $633.6M (as of Mar 2023).

What percentage of Sonnet BioTherapeutics is owned by WALLEYE CAPITAL LLC?

As of Mar 2023, WALLEYE CAPITAL LLC holds 1.66M shares of Sonnet BioTherapeutics (SONN), compromising 38.65% of the company, valued at $599.25M.

What percentage of Sonnet BioTherapeutics is owned by SABBY MANAGEMENT, LLC?

SABBY MANAGEMENT, LLC is the third largest holder of Sonnet BioTherapeutics. The company owns 1.22M of the company's shares outstanding (worth $437.59M).